Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on ...

February 25, 2009 — In premenopausal women with early breast cancer, adjuvant therapy with the luteinizing hormone-releasing hormone agonist goserelin (Zoladex, AstraZeneca) decreases the long-term ...

Review the side-effects of Goserelin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

All premenopausal women who had been treated with goserelin and anastrozole for advanced breast cancer in the Nottingham Breast Unit were included in the study. A total of 16 such patients with a mean ...

Ovarian failure is a common toxic effect of chemotherapy, and previous studies evaluating the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function showed mixed results.

Goserelin is a type of hormone therapy called a luteinising hormone blocker . This means it stops the release of luteinising hormone (LH) from the pituitary gland . Hormones are natural substances ...

Details concerning the Goserelin medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and injections.

Comparative real-world survival and prescription patterns of darolutamide versus apalutamide in non-metastatic hormone-resistant prostate cancer. This is an ASCO Meeting Abstract from the 2026 ASCO ...

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi Secondary analysis of the Stockholm ...

This page is about goserelin for prostate cancer. We have information about goserelin for breast cancer. Goserelin is a type of hormone therapy called luteinising hormone blocker ( LH blocker ). This ...

Goserelin, a lutenizing hormone-releasing hormone agonist, reduces the long-term risk of disease recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen, ...

Goserelin, a lutenizing hormone-releasing hormone agonist, reduces the long-term risk of disease recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen, ...